Table 1. Effect of *C. odollam* extract on the growth of human-derived cancer cells.

	Breast carcinoma			**Colon carcinoma**		**Pancreatic carcinoma**	**Nasopharyngeal carcinoma**	**Small lung carcinoma**	**Liver carcinoma**	**Human foetal lung fibroblast cells**
Cells	**MCF-7**	**MDA-MB-231**	**SKBR-3**	**HCT-116**	**HT29**	**Panc-1**	**HK-1**	**A549**	**HepG2**	**MRC-5**
Mean GI_{50} ± SD (µg/mL)[a]	0.062±0.006	0.17±0.02	0.088±0.009	0.03±0.005	0.07±0.01	0.06±0.017	0.03±0.67	0.05±1.00	0.05±1.43	146±1.56
SI[b] compared to the **MRC-5** cells	2354	858	1659	4866	2085	2212	4866	2920	2920	

Mean± SD GI_{50} values were determined by MTT assays following 72 h exposure of cells to *C. odollam* extract (n=4) and expressed as a mean ± SD of ≥3 independent trials. [a]GI_{50}: 50% *g*rowth inhibition, [b]SI: Selectivity index (GI_{50} MRC-5 / GI_{50} cancer cell line).

Table 2. Effect of CR on the growth of human-derived cancer cells.

	Breast carcinoma				**Colon carcinoma**			**Pancreatic carcinoma**		**Nasopharyngeal carcinoma**	**Small lung carcinoma**	**Liver carcinoma**	**Human foetal lung fibroblast cells**	**Normal nasopharyngeal epithelial cells**
Cells	**MCF-7**	**MDA-MB-231**	**MDA-MB-468**	**SKBR-3**	**HCT-116**	**HT29**	**VR-HCT-116**	**Panc-1**	**MIA PaCa-2**	**HK-1**	**A549**	**HepG2**	**MRC-5**	**NP-69**
Mean GI_{50}[a] ± SD (nM)	28.2 ±2.80	42.8 ±5.26	73.7 ±0.69	130.2 ±6.14	60.1 ±1.27	55.1 ±2.75	69.6 ±1.03	23.6 ±3.62	90 ±2.66	22.3 ±0.67	45.8 ±1.00	69.3 ±1.43	41100 ±1560	> 3467
SI[b] compared to the **MRC-5** cells	1457	967	557.36	315	683	745	590	1740	456	1838	896	592		
SI[b] compared to the **NP-69** cells	122.9	81.02	47	26.6	57.7	62.9	49.8	146.9	38.5	155.5	75.7	50		

Mean± SD GI_{50} values were determined by MTT assays following 72 h exposure of cells to test CR (n=4) and expressed as a mean ± SD of ≥3 independent trials. [a]GI_{50}: 50% *g*rowth inhibition, [b]SI: Selectivity index (GI_{50} of MRC-5 or NP-69 cells / GI_{50} of cancer cell line).

Table 3 Predicted pharmacokinetic parameters of CR following intravenous, oral and subcutaneous administration at 10 mg/kg in mice

Parameters	Route of administration		
	Intravenous	**Oral**	**Subcutaneous**
F_a	-	99.9	-
F	-	61.2	96.6
C_{max} (μg/mL)	12.3	3.9	1.2
T_{max} (h)	-	0.4	1.2
AUC_{inf} (μg·h/mL)	6.3	3.9	6.1
CL_h (mL/h)		39.0	
CL_r (mL/h)		1.0	

F_a, fraction absorbed; F, bioavailability; C_{max}, maximum concentration in plasma; T_{max}, time of maximum concentration in plasma; AUC_{inf}, area under the concentration-time curve from time zero to infinity; CL_h, hepatic clearance; CL_r, renal clearance.